News

Dr. Shapiro discusses the implantable VC-02 device success in producing C-peptide in patients with type 1 diabetes and what is coming next.

Investigators developed the first module to confront implicit bias toward patients with sickle cell disease on an individual or personal level.

A high-potential drug for type 1 diabetes may not have received regulation this year, but it sparked vital conversation among experts.

An outpatient care coordinator discusses the systemic and psychiatric symptoms of COVID-19 long haulers, as well as differences in outcomes based on vaccination.

Allergists discuss the differing opinions of allergies and optimizing patient care during the COVID-19 pandemic.

Higher body mass index was seen as a protective factor for C difficile infections.

The data regarding the safety and efficacy of fecal microbiota transplantation for patients with C difficile infections and inflammatory bowel disease has been limited.

Patients in a racial and ethnic minority group were less likely to state they were treated with respect by their clinician compared with non-Hispanic White patients (AOR, 0.77).

Influenza A has been the dominant strain during the current influenza season.

The American Society of Hematology debuted its Health Equity Rounds series, which are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates.

Engagement had positive associations with higher comfort with technology, visual acuity, nAMD diagnosis, and the number of intravitreal injections.

Patients with COVID-19 were not at an increased risk of developing CDI.

A look into how Allegheny Health Network launched its multi-specialty referral system for post-hospitalized COVID-19 patients.

Dr. Moody speaks to how these E/M code changes affect billing documentation and patient care.

Children with persistent sleep problems had greater impairments across the different outcomes other than cognitive skills.

Dr. Jellinger discusses the lipid section of the DCRM guidelines, the role of combination therapies in lowering LDL and what is coming next for the field of diabetes in 2022.

The clinical program has been suspended for patients that are under the age of 18 after an adolescent patient developed persistent anemia.

Results from the RELIEVE-AD study were consistent with patient-reported outcomes in clinical trials.

Apremilast is now the first and only treatment approved in adult patients with plaque psoriasis across all severities.

NYU Langone is developing a comprehensive care program that includes psychiatric evaluations during postpartum OBGYN care.

Investigators suggested a more efficient sleep diagnosis algorithm be created to detail the connection between ADHD and sleep in children.

Data show the proportion of infants with influenza aged <6 months ranged from 1.0 – 2.6% among all infant hospitalizations in the 2019 influenza season.

The TPV system expands transcatheter therapy options for patients with congenital heart valve disease.

Both PEARL 1 and PEARL 2 enrolled over 2000 adults and adolescents patients selected from 48 countries.

The treatment is approved as either a monotherapy or an adjunctive therapy with either lithium or valproate.

Dr. Rosmarin details the TruE-V clinical trial, and speaks to what could eventually be the first FDA approved medicine for vitiligo.

Weight loss could be beneficial for NASH and NAFLD patients.